Scientific **EXCELLENCE**

Devoted to finding the next scientific breakthrough, these industry leaders are at the forefront of drug discovery and development.



hrough a dedication to scientific excellence and her positive influence on others, Marie Foegh, M.D., has had a powerful impact on students, colleagues, as well as millions of women around the world.

Dr. Foegh is a truly gifted scientist, leader, and genuine advocate for improving women's health options. Her unique combination of clinical, research, and regulatory experience in both the U.S. and European arenas provide an unmatched ability to navigate tough clinical trial design, analysis, and interpretation decisions. Her ability to understand and interpret data and to present information in a usable framework offers a compelling approach that demands attention and influences thinking.

Her commitment to her work and to improving women's health is a refreshing contrast to common bottom-line viewpoints, while at the same time she respects financial realities. It remains her goal to get as many products as possible on the market that benefit women's health.

Her many corporate achievements, includ-

ing contributing to the development of ground-breaking contraceptives such as Yasmin, Yaz, and Mirena, reflect Dr. Foegh's effective management style of setting aggressive goals and empowering her people with the tools and motivation required to reach them.

Dr. Foegh has a legacy of building strong relationships with her colleagues

She also has inspired hundreds of students over the years in her role as an adjunct professor at Georgetown University Medical School's Department of Medicine, Division of Nephrology and Hypertension.

Her scientific discoveries have been published in more than 150 peer-reviewed articles and have influenced scientists around the world.

Dr. Foegh's influence on thought leaders and regulators is testament to her

solid appreciation of the truly important aspects of encouraging out-of-the-box thinking in the public-health arena.



Dr. Elliot EHRICH Leading an R&D Transformation

hen Elliot Ehrich, M.D., joined Alkermes in 2000, it was known as a drug delivery company, applying sophisticated technologies to transform existing drugs into long-acting medications for patients with chronic diseases. His inspirational leadership has led to some significant changes, most notably by shaping and evolving the company's R&D culture.

Dr. Ehrich has been a champion for building the clinical case for how these long-acting medications had a value far beyond merely

Dr. Jerry BOSCIA Steering the Research Ship

erome (Jerry) A. Boscia, M.D., has developed a series of compounds over his long tenure in industry, all along the way staying focused on improving the lives of patients.

And while his true passion is developing new drugs to prevent and treat medical illnesses, he is just as focused on developing his team and providing opportunities for his colleagues to learn, engage and grow.

One of his colleagues commented, as a leader, Dr. Boscia is preparing all of us to understand and prepare for the complexity and challenges ahead by embracing diversity on many levels, while focusing on patients' needs as the most important goal.

Those who have had the pleasure of working with him over his 30 years both in an academic setting and in the biopharmaceutical industry, say Dr. Boscia is both an inspirational and pragmatic leader. He inspires by his unrelenting dedication to protecting patients from harm while maximizing patient benefit. He has had an unwavering focus on maintaining a voice for patients in the research and development organizations of two major companies. All the while he has led his organizations to unparalleled success in providing transforma-

tional medicines in infectious diseases, oncology, and immunology, with more than 18 U.S. FDA approvals during his tenure with Centocor Research & Development and Janssen Research & Development alone.

Dr. Boscia is loyal, decisive, and makes his choices using a finely tuned moral compass that has served everyone well, including patients, his team, and the company.

These qualities have attracted and maintained a superb team. His team

members follow his example and stay at Janssen R&D because of him and his clear and honest

PASSIONATE. DEDICATED

NAME: Jerome Boscia, M.D.

Did You Know?

won Johnson & Johnson's

Standards of Leadership

Dr. Jerry Boscia

CURRENT POSITION: Head, Immunology Development, Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson

DATE AND PLACE OF BIRTH: December 1951; Easton, Pa.

EDUCATION: Franklin & Marshall College; M.D., Temple University School of Medicine

FIRST JOB: Medical College of Pennsylvania

FIRST INDUSTRY-RELATED JOB: Smith Kline & French

PROFESSIONAL MENTORS: Donald Kaye, M.D.; William Packer; Baron Jean Stéphenne

AWARDS AND HONORS: Johnson & Johnson Standards of Leadership Awards

GIVING BACK: American Cancer Society






Dr. Jerry Boscia is

ledicated to discovering,

Dr. Elliot Ehrich's leadership, vision, and day-to-day connections touch the work of hundreds of scientists with whom he works.

Did You Know?

Dr. Elliot Ehrich is a rabid cruciverbalist — a competitive crossword puzzler.



Dr. Ehrich recognizes that interest and passion aren't sufficient to accomplish big and complex goals — be that in drug development or life — and what is required is strong determination. His spirit for pursuing new science, his ability to motivate teams of talented researchers to achieve great things in new drug development, and his steadfast commitment to the ultimate goal of helping patients inspire those around Dr. Ehrich.

Those who work with him say he encourages outside-the-box thinking and enables others to be more creative in the ways they conduct research studies, expand their analysis, and extend the impact of their work through engaging with a broader range of researchers in and outside of Alkermes.

Always eager to learn and develop, Dr. Ehrich continues to be mentored by a small group of former leaders at Merck Research

Regardless of his busy full-time role as senior VP of research and development and chief medical officer at Alkermes, Dr. Ehrich always

DETERMINED. CONNECTING.

NAME: Elliot W. Ehrich, M.D.

CURRENT POSITION: Senior VP, Research and Development, Chief Medical Officer, Alkermes Inc.

The Researchers & Scientists

DATE AND PLACE OF BIRTH: March 1959; Marblehead, Mass.

EDUCATION: B.A., biochemistry, Princeton University; MD, Columbia University

FIRST JOB: Internal medicine residency, rheumatology fellowship training, immunology post doc training, Stanford University

FIRST INDUSTRY-RELATED JOB: Clinical pharmacology, Merck

ALTERNATIVE PROFESSION: Computer programming

PROFESSIONAL MENTORS: Leaders at Merck Research Labs

PROFESSIONAL ASSOCIATIONS: American College of Rheumatology


WORDS TO LIVE BY: Bad things and goods things are both transient — accept that

CONNECTED VIA: LinkedIn

finds time to offer his help to those who ask, willingly rolling up his sleeves to lend a hand. He also mentors many young scientists and physicians at early stages in their career, not because he wants to be

smart or share good ideas, but because he believes it's important to foster growth and maturity in the next generation.





convenience — that they could provide im-

new long-acting medications succeeded through

drug approval and launch, each with the poten-

tial to make a major impact for millions of pa-

tients: Risperdal Consta for schizophrenia and

bipolar disorder, Vivitrol for alcohol and opioid

dependence, and Bydureon for Type 2 diabetes.

mes' R&D group to be capable of developing

novel — not reformulated — drugs. Beginning

His next challenge was to transform Alker-

He led the Alkermes' R&D vision as three

proved clinical outcomes for patients.

Dr. Jerome BOSCIA

Patient-Focused

erry Boscia, M.D., is a well-renowned research physician and a drug development expert. He has a wealth of experience in successfully developing innovative drugs and biologics, including Remicade, Simponi, and Stelara for variety of immune-mediated inflammatory diseases; vaccines for hepatitis B and hepatitis A; a variety of anti-microbials for infectious diseases; and Hycamtin in oncology. His insights and success in product development are unsurpassed in the pharmaceutical industry.

Dr. Boscia began his medical career as a research physician focusing on antimicrobial work resulting in 30 publications, and he authored several book chapters in the areas of anti-microbial research and vaccines.

After his academic career, he joined Smith Kline & French to help develop a portfolio of vaccines. Later, his responsibilities expanded to disease areas, including infectious diseases and inflammation, tissue repair, and oncology.

In the past 12 years while at Centocor R&D and Janssen R&D, in addition to advancing multiple compounds through clinical development and approval for immune-mediated inflammatory diseases, Dr. Boscia has been a major contributor in developing Remicade into a transformational medicine for so many patients living with Crohn's disease, rheuma-

Getting Personal with DR. JERRY BOSCIA

FAMILY: Wife, Diane; daughter, Michele

HOBBIES: Triathlons: swimming, cycling, and running

READING LIST: The New England Journal of Medicine; The Journal of the American Medical Association; The Lancet; and The Pink Sheet

FAVORITE BOOK: Catch-22

FAVORITE MOVIE: The Godfather


FAVORITE SMARTPHONE APP: Google

MOST UNUSUAL PLACE VISITED: Dakar, Senegal

toid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and plaque psoriasis — an accomplishment that he considers to be a career highlight.

As a leader, Dr. Boscia's actions are based on integrity and the highest ethical standards. He has established and created trusting relationships with his staff, his colleagues, and key decision makers of major health authorities in the United States, European Union, and elsewhere.

Dr. Boscia understands the risk of drug development and knows how to manage and mitigate the risk. As a decision-maker, Dr. Boscia is confident in his knowledge and thought process in considering all of the possibilities as well as probabilities. He also creates an environment that allows others to attempt innovative solu-



tions while taking appropriate risks. He leads, inspires, and motivates everyone on the teams to the common goal in creating innovative medicines to benefit patients.

Many patients are grateful to Dr. Boscia for his dedication and commitment in developing such important medicines. However, he is only somewhat content, although his dream of helping patients has become a reality, his dream continues.

Dr. Marie FOEGH

Female Agility

board certified OB/GYN, Marie Foegh, M.D., has dedicated herself to the development of safer and more convenient contraceptive options for women.

Over last 20 years, Dr. Foegh has led the clinical organizations of major pharmaceutical and biotech companies both in the United States as well as Europe. Thanks to her leadership in the clinical development of market leading products, including Yasmin, Yaz, and Mirena, millions of women around the world are benefiting from new contraceptive options.

Dr. Foegh currently serves as the chief medical officer and VP of clinical research and development for Agile Therapeutics, a company dedicated to women's health.

She has played a pivotal role in the development of Agile's main product, AG200-15, a low-dose, once-weekly contraceptive patch that has been filed with the FDA for approval.



Getting Personal with DR. MARIE FOEGH



HOBBIES: Skiing; sailing; music; theater

daughters

FAVORITE BOOK: Girl With the Dragon Tattoo

FAVORITE MOVIES: The King's Speech; The Queen; The Iron Lady

BUCKET LIST: Getting a pilot's license

FAVORITE SMARTPHONE APPS: Epocrates; TravTracker

LIFE LESSONS: If you keep trying, you always get it right

MOST UNUSUAL PLACE VISITED: Greenland

UNDER THE CLOAK OF INVISIBILITY: The West Wing

TIME TRAVEL: To the future to travel to Mars

Her achievements helping women with new contraceptive options are some of the accomplishments she is most proud.





Dr. Elliot Ehrich aspires and works to create connections around a single idea or concept.

n his commitment to the advancement of valuable medicines, Elliot Ehrich, M.D.'s, leadership extends beyond the walls of

He has a long-standing commitment to making a difference in new ways to treat addiction, including spearheading a major collaboration with NIDA (the National Institute on Drug Addiction) on a program for the treatment of cocaine dependence.

This requires substantial time, energy, and expertise to marshal through the process of obtaining funding and implementation. With the

Dr. Elliot EHRICH Committed to Outcomes

failure of so many individual medications that have been tested for cocaine dependence, Dr. Ehrich proposed a study to test the effects of two different medications in combination, each with a different and potentially complementary effect on receptors in the brain.

Dr. Ehrich's passionate leadership with the NIDA program is just one example of the many ways he is a driving force behind research for new drug development.

He also remains connected to the professional medical community through his role for 15 years as a volunteer and adjunct professor for medical students at the Robert Wood Johnson Medical School.

He serves on the advisory board of other biotechnology companies, including Heptares Therapeutics and AileronTherapeutics.

Dr. Ehrich says the most creative and innovative things happen when people with orthogonal approaches and perspectives come together around a single idea or concept.

He actively aspires and works to create those connections.

The challenge in the discovery of new medicines that bring value to society, he maintains, is balancing new science with clinical empiricism. Empiricism was the inspiration for all early medicines. Many "new" medicines of the 1980s and 1990s were largely refinements of empirically based medicines. The challenge today is to balance the attractiveness of a novel target derived for advanced screening techniques with pathways that are empirically known to influence human physiology based on empiric experience.

Getting Personal with DR. ELLIOTT EHRICH



FAMILY: Wife, Nancy Donovan; Son William, 21; daughter Fiona, 17

HOBBIES: Sailing

FAVORITE BOOK: Spartina by John Casey

BUCKET LIST: Take his wife to all four Grand Slam tennis tournaments

FAVORITE SMARTPHONE APP: Amazon Kindle

INSPIRED BY: Risk takers, starting with Ikarus

LIFE LESSONS: It is ok to be stubborn and ignorant but not both at the same time

3rd Annual Executing Global Clinical Trials

September 13 - 14, 2012

Fairmont Copley Square Hotel, Boston, MA

HIGHLIGHTS

2012 KEYNOTES ON ASIA/ **EMERGING MARKETS**



Debra S. Barker, MD Chief Scientific Officer, **Emerging Markets Novartis**



Christopher Gallen, MD, PhD CEO SK Bio-Pharmaceuticals

- ✓ Risk Based Monitoring What Does it Mean for Your Global Study?
- ✓ Re-Thinking How We Globalize Outsourcing
- ✓ Reducing Risk in Placebo Response in Global Clinical Research
- ✓ Investigator Non-Compliance and Protocol Deviation
- Social Media Techniques and Mobile Technologies Update
- ✓ Conducting Global Trials for Rare Diseases

- PLUS -

Country-Specific Roundtables

China • EU • Latin America • India • Russia/Ukraine Canada • Brazil • Eastern Europe • Australia • Korea

Executive Sponsors



Organized by







PharmaVoice readers with code PVGCT

15% off for

Lead Media Partner

